2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11C.03 Anlotinib Combined with Immune Checkpoint Inhibitor May Benifit Advanced Smarca4-Deficient Thoracic Tumor Patients in First Line

EP.11C.03 Anlotinib Combined with Immune Checkpoint Inhibitor May Benifit Advanced Smarca4-Deficient Thoracic Tumor Patients in First Line

Back to course

Pdf Summary

The study explores the potential benefits of anlotinib combined with immune checkpoint inhibitors (ICIs) as a first-line treatment for patients with advanced SMARCA4-deficient thoracic tumors, a rare and difficult-to-treat cancer. Given that the optimal first-line treatment strategy remains unclear, this research aims to identify effective approaches.<br /><br />The study involved analyzing the clinical and pathological data of 55 patients, including those with SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) and SMARCA4-deficient undifferentiated tumors (SMARCA4-dUT). The results indicated that patients receiving anlotinib combined with immunotherapy had better progression-free survival (PFS) compared to those who received chemotherapy combined with immunotherapy (PFS was not reached versus 8.63 months, p=0.05).<br /><br />Furthermore, the survival analysis demonstrated a trend toward longer overall survival (OS) for patients who received immunotherapy in the first line compared to those who received it later or not at all. Specifically, the median OS was 21.67 months for first-line immunotherapy patients, compared to 6.07 months for those treated later and 8.57 months for those not receiving immunotherapy at all (p=0.004).<br /><br />The study concludes that early intervention with immune checkpoint inhibitor-based treatments could lead to better survival outcomes for patients with SMARCA4-deficient thoracic tumors compared to other treatment options. Additionally, combining ICIs with anti-angiogenesis therapy might represent a superior first-line treatment strategy. No conflicts of interest were disclosed by the authors.<br /><br />The findings suggest promising directions for future treatment protocols, emphasizing the importance of immunotherapy, particularly when combined with anlotinib, in managing these challenging thoracic tumor cases.

Asset Subtitle

Wei Zhang

Meta Tag

Speaker Wei Zhang

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

anlotinib

immune checkpoint inhibitors

SMARCA4-deficient thoracic tumors

first-line treatment

progression-free survival

overall survival

immunotherapy

anti-angiogenesis therapy

non-small cell lung cancer

treatment strategy